RARE has been in the news 643% more than usual
Feb 10, 2026, 1:32 PM
-7.58%
What does RARE do
Ultragenyx Pharmaceutical, based in Novato, California, focuses on developing therapies for rare genetic diseases and has four approved products, including Crysvita and Mepsevii. The company went public on January 31, 2014, and employs 1,276 people.
RARE has been in the news recently: Rosen Law Firm, Schall Law Firm, and DJS Law Group have filed or announced class actions or solicitations involving Ultragenyx Pharmaceutical Inc. (RARE) for shareholders who bought stock between August 3, 2023 and December 26, 2025.
These firms state an April 6, 2026 deadline for investors to contact them or join the cases.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.